awmsg logo



ramucirumab (Cyramza®)


Reference No. 2141

Publication date:
29/11/2019


Appraisal information

ramucirumab (Cyramza®) intravenous infusion


Company: Eli Lilly & Co Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/11/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ramucirumab (Cyramza®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with advanced hepatocellular carcinoma with a baseline alpha-fetoprotein 400 ng/mL after prior sorafenib therapy
Statement of Advice (SOA)
Download